SCHEMBL7124335

SCHEMBL7124335

Clc1ccc(Cl)c(SCCCCN2CCN(C3=COC(C4=CC=CCC4)=CO3)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
TMEM97 Q5BJF2 2/20 0.33
HTR1A P08908 3/20 0.32
ADRA1B P35368 3/20 0.32
DRD2 P14416 2/20 0.32
HTR2A P28223 2/20 0.32
DRD1 P21728 1/20 0.32
DRD5 P21918 1/20 0.32
DRD3 P35462 1/20 0.32
KCNH2 Q12809 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
KDM4E B2RXH2 2/20 0.31
THRB P10828 3/20 0.31
GAA P10253 1/20 0.31
HTR7 P34969 1/20 0.30
HTR6 P50406 1/20 0.30
ADRA1A P35348 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7117421 0.97 CYP1A2 (0.48) CYP1A2CYP2D6TMEM97HTR1AADRA1B
SCHEMBL7130726 0.94 CYP1A2 (0.40) CYP1A2CYP2D6TMEM97HTR1AADRA1B
SCHEMBL7124269 0.93 CYP1A2 (0.36) CYP1A2CYP2D6TMEM97HTR1ADRD2
SCHEMBL7128484 0.90 KDM4E (0.35) CYP1A2CYP2D6HTR1AADRA1BDRD2
SCHEMBL7123088 0.87 THRB (0.36) HTR1ADRD2HTR2ADRD1DRD5
SCHEMBL7119994 0.87 CYP1A2 (0.32) CYP1A2CYP2D6TMEM97HTR1AADRA1B
SCHEMBL7128124 0.87 KDM4E (0.34) CYP1A2CYP2D6HTR1AADRA1BDRD2
SCHEMBL7124370 0.86 HTR1A (0.34) TMEM97HTR1AADRA1BDRD2HTR2A
SCHEMBL7120263 0.85 KDM4E (0.34) HTR1AADRA1BDRD2DRD3KCNH2
SCHEMBL7126603 0.84 DRD2 (0.36) CYP1A2CYP2D6TMEM97HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US claimed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP claimed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO claimed
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US disclosed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP disclosed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use CRBN, CDR2, DRD3 CYP1A2 770/4885CYP2D6 353/4885TMEM97 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.